Why is Ionis Pharmaceuticals stock down 4.7% today?

Why is Ionis Pharmaceuticals stock down 4.7% today?
Ionis Pharmaceuticals slides 4.74% today

Ionis Pharmaceuticals (IONS) dropped 4.74% after investors reacted to data showing its therapy pelacarsen did not meet the primary endpoint in the HORIZON cardiovascular trial, even as positive phase 3 results for ulefnersen in ALS were announced. The down move is supported by bearish technicals, with IONS trading below its key moving averages and oversold momentum indicators confirming persistent selling interest.

IONS price prediction
24H 0.95%
$27.65
48H 1.64%
$27.84
7D 1.57%
$27.82
1M -50.6%
$13.53
3M -46.55%
$14.64
6M -49.58%
$13.81
12M -70.46%
$8.09
Current price: $27.39 0.4650 1.73%
Closed 11/18
Daily range 26.70 Arrow from to Icon 28.04
Weekly range 26.55 Arrow from to Icon 29.90
Loading...

Highlights

  • Ionis Pharmaceuticals announced positive phase 3 data from the FUSION study, showing clinical benefit for ulefnersen in ALS patients.
  • Pelacarsen did not meet its primary endpoint in the HORIZON trial for cardiovascular risk, and shares remain under broad selling pressure despite ongoing licensing and partnership revenues.
  • Ionis Pharmaceuticals stock trades below key moving averages with technical signals showing oversold conditions and a forecasted range of $42.11 to $46.5 over the next five days.

Ongoing selling pressure as positive ALS data contrasts with trial miss

Ionis Pharmaceuticals released positive phase 3 results from the FUSION study, showing meaningful clinical benefit for ulefnersen in ALS patients. The company also reported that pelacarsen failed to meet its primary endpoint in the HORIZON trial targeting cardiovascular risk. Ionis continued to highlight partnerships and licensing activities for revenue generation, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, is skeptical after Ionis Pharmaceuticals' failed pelacarsen endpoint overshadowed positive news on ulefnersen. He notes that persistent bearish technicals, deeply oversold readings, and consecutive closes below major averages indicate continued exit by investors. Kharitonov also points to lackluster sentiment, with the market ignoring recent positive trial results and focusing on the HORIZON trial disappointment. He questions whether management's revenue efforts can offset ongoing negative momentum as sellers dominate the tape. "The technicals are in firm control here — without a sustained catalyst, buyers look set to remain sidelined," Kharitonov warns.
Viktoras Karapetjanc, expert at Traders Union, remains constructive despite the recent sell-off. He sees the latest ulefnersen phase 3 success as evidence of strong long-term fundamentals and believes Ionis' partnership-driven model ensures future revenue streams. Karapetjanc emphasizes that current market conditions offer strategic entry points for patient investors, especially with broader volatility presenting opportunity. "Market offers multiple setups and further growth is expected once sentiment recovers around positive late-stage data," Karapetjanc asserts.
Jainam Mehta, market strategist, takes a neutral stance given sharply oversold oscillators and downside momentum. He highlights the potential for a tactical bounce if prices reclaim $46.5, but remains cautious until technical confirmation appears. Mehta notes divergence in the Hull MA versus other indicators as a possible contrarian signal. "A short-lived upside move could materialize, but I would avoid significant positioning unless the resistance break is clean," Mehta says.
Ionis Pharmaceuticals asset chart
Ionis Pharmaceuticals price dynamics. Source: TradingView.

Downward momentum persists as all technicals point to weakness

IONIS trades below its 20-day ($54.82), 50-day ($55.49), and 200-day ($71.82) moving averages, indicating persistent downward momentum across all timeframes. The alignment of the 50-day and 200-day averages confirms a bearish structure. Resistance is at $44.28 and support is at $42.11. Momentum remains weak, as MACD and ADX signal a sell bias. The RSI at 29.71 and CCI at -113.32 show oversold conditions, while BBP at -3.94 and the negative Awesome Oscillator reading reinforce the dominance of sellers. Today's session opened with a downside gap and the stock is trading near its low, with intraday volatility at 3.50%. A modest technical divergence is present as the Hull Moving Average gives a buy signal, but all other core indicators remain bearish.

Previously it was reported that Ionis Pharmaceuticals was exhibiting persistent technical weakness amid dominant bearish momentum. The latest developments reinforce that downside risk remains elevated, making $42.11 a critical support level for traders to monitor in the near term.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.